Paul Scherrer Institute (PSI), Center for Proton Therapy, Villigen PSI, Switzerland
Proton therapy is a high-precision radiotherapy technique. Since 1996,image guided proton therapy (IGPT) has been applied at PSI, using the spotscanning technique. Patients are positioned and imaged remotely at a dedicatedCT. In addition, the second generation Gantry 2 with an in-room sliding CT wastaken into operation in November of 2013. Fixation of the head is achieved bybite block or mask. In the prone position, we mold a special head support whichfacilitates a reproducible and comfortable position for fixation. In smallchildren, special care must be taken in forming the moulage to ensure that theairways are kept free. On a daily basis, a patient'spositioning is checked by means of orthogonal CT scout images. When theposition is correct, the patient is transported with a robotic transport systemto the treatment station, Gantry1, while maintaining the fixed position. We estimate that our remote patientpositioning method facilitates a patient throughput of up to 40% higher thaninroom positioning, because the often time-consuming process of positioningand imaging takes place outside the treatment room. In addition, and in contrast tophoton therapy, proton therapy is very sensitive to range changes. It istherefore important that during the daily pre-treatment imaging process,changes in the patient's anatomy (such as weight gain or loss) or body cavities(e.g. swelling due to sinusitis) need to be monitored and taken into account. Based on a comprehensive analysis of300 patients, it has been established that we achieve a positioning accuracy ofless than 2 mm for head and neck cases. After almost 20 years of clinicaloperation, the proton delivery system at PSI has proven its reliability. In the future, there will be a newchallenge: The spot scanning technique will be used with Gantry 2 for targetsin motion, as in the lung. In developed countries, the total expenditures on health care have shown an almost continued increase over the last decades, and, not unexpectedly, the cost of cancer care has not been spared of this steady growth. The economic impact of health -and cancer -care can be measured as total spending, percent of national gross domestic product (GDP), or the cost to care for a single patient. In 2010, the European Union member states devoted an average of 9.0% of their GDP to health spending, a significant increase from the 7.3% spent in 2000, but a slight decline compared to the peak of 9.2% reached in 2009, consequence of the economic crisis affecting many countries as of the middle of 2008. In Europe, cancer care costs consume about 5% of the global health care budget, ranging between 4.1% and 7%. To the best of our knowledge, radiotherapy only consumes bout 5% of the global cancer care budget. The variation in cancer care expenditures is more striking when focusing on the annual amount of money spent per capita: whereas the European average is 2,441€, some
